Abstract
GRWD1, a novel WD40-repeat-containing protein designated glutamate-rich WD repeat, is highly expressed in CRC and participates in a series of oncogenic activities. However, the cause of GRWD1 overexpression and its oncogenic mechanism in CRC remains elusive. This study revealed that GRWD1 was correlated with inflammation and was progressively upregulated during the progression of Azoxymethane/Dextran sodium sulfate (AOM/DSS) in a mouse model. Moreover, GRWD1 was activated by the IL-6/STAT3 signal pathway in CRC cells. Besides, it promoted the degradation of p53 and further induced GLUT1 to facilitate aerobic glycolysis in CRC. Taken together, GRWD1 played an oncogenic role in tumorigenesis of CRC and represented a promising therapeutic target.